caus
sever
acut
respiratori
syndrom
result
symptom
fever
cough
short
breath
viru
also
suggest
initi
cytokin
storm
patient
evidenc
elev
cytokin
creactiv
protein
crp
report
preliminari
data
patient
develop
pneumoniaacut
respiratori
distress
syndrom
ard
particip
compassionateus
program
papa
giovanni
xxiii
hospit
bergamo
itali
patient
receiv
intraven
siltuximab
chimer
mab
bind
block
effect
dose
rang
mg
median
mg
median
age
patient
treat
year
patient
follow
median
eight
day
serum
crp
level
reduc
patient
avail
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
data
follow
treatment
improv
clinic
condit
observ
patient
patient
stabil
evidenc
clinic
relev
chang
condit
experienc
worsen
condit
patient
experienc
worsen
condit
one
patient
die
one
patient
experienc
cerebrovascular
event
analysi
present
inform
medic
commun
potenti
role
siltuximab
treat
patient
ard
secondari
infect
cohort
studi
patient
treat
standard
therapi
hospit
ongo
report
mortal
rate
upon
complet
introduct
caus
sever
acut
respiratori
syndrom
result
symptom
fever
cough
short
breath
sarscov
middl
east
respiratori
syndrom
cov
merscov
highli
pathogen
coronavirus
infect
lower
respiratori
tract
caus
sever
pneumonia
result
rapid
viral
replic
massiv
inflammatori
cell
infiltr
elev
proinflammatori
cytokin
level
includ
creactiv
protein
crp
lead
sever
respiratori
failur
describ
acut
respiratori
distress
syndrom
ard
channappanavar
r
perlman
viru
also
suggest
initi
cytokin
storm
patient
mehta
p
et
al
blockad
identifi
potenti
strategi
mitig
complic
associ
infect
tocilizumab
target
monoclon
antibodi
mab
receiv
rapid
approv
china
treatment
patient
sever
extens
lung
damag
nation
health
commiss
china
xu
x
et
al
report
preliminari
data
patient
develop
seriou
respiratori
complic
treat
siltuximab
chimer
mab
bind
block
effect
siltuximab
approv
european
medicin
agenc
food
drug
administr
usa
treatment
adult
multicentr
castleman
diseas
human
immunodefici
viru
human
herp
neg
eusa
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
method
investigatorl
studi
retrospect
analys
data
collect
patient
pulmonari
infect
confirm
clinic
radiolog
assess
ard
accord
berlin
criteria
definit
task
forc
ard
admit
papa
giovanni
xxiii
hospit
bergamo
itali
patient
treat
accord
hospit
standard
care
receiv
treatment
siltuximab
administ
intraven
dose
mgkgday
hour
second
dose
could
administ
physician
discret
part
compassionateus
program
approv
hospit
ethic
board
data
analysi
complet
march
patient
least
day
followup
siltuximab
administr
patient
legal
repres
provid
consent
particip
studi
march
march
patient
confirm
admit
hospit
median
age
patient
year
rang
year
men
women
treat
patient
male
fever
present
symptom
patient
patient
dri
cough
patient
dyspnea
tabl
preval
comorbid
group
patient
hypertens
cardiovascular
diseas
diabet
patient
respect
addit
one
patient
malign
one
patient
cerebrovascular
diseas
one
patient
chronic
kidney
diseas
baselin
serum
crp
result
elev
patient
median
mgdl
rang
mgdl
level
avail
patient
outsid
normal
rang
median
pgml
rang
pgml
tabl
partial
pressur
arteri
oxygen
fraction
inspir
oxygen
ratio
avail
patient
baselin
median
valu
rang
patient
studi
requir
ventil
either
continu
posit
airway
pressur
cpap
noninvas
ventil
niv
patient
receiv
siltuximab
median
dose
mg
rang
mg
tabl
five
patient
receiv
second
dose
siltuximab
three
five
patient
infus
two
day
apart
two
patient
infus
three
day
apart
patient
treat
siltuximab
within
two
day
initi
ventil
either
cpap
niv
median
followup
patient
eight
day
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
follow
treatment
siltuximab
serum
crp
level
reduc
within
normal
rang
day
remain
stabl
patient
avail
data
throughout
followup
period
figur
addit
patient
experienc
improv
condit
reduc
need
ventil
ie
patient
remov
cpap
niv
patient
experienc
stabil
condit
patient
experienc
worsen
condit
requir
intub
tabl
one
patient
develop
cerebrovascular
event
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
compassionateus
program
initi
understand
feasibl
suppress
crp
product
siltuximab
improv
outcom
patient
requir
cpap
niv
pneumoniaard
treatment
initi
evid
china
first
case
emerg
indic
excess
product
inflammatori
marker
crp
correl
sever
diseas
chen
x
et
al
conti
p
et
al
diao
b
et
al
gong
j
et
al
liu
et
al
yang
et
al
mani
studi
report
signific
increas
crp
level
patient
sever
critic
compar
patient
mild
diseas
cai
et
al
chen
j
et
al
feng
c
et
al
huang
et
al
liu
j
et
al
qin
c
et
al
ruan
q
et
al
shi
et
al
wang
et
al
wang
z
et
al
wu
c
et
xu
w
et
al
xu
x
et
al
zeng
q
et
al
zhao
z
et
al
zhang
b
et
al
zhou
f
et
al
zhou
et
al
similarli
data
retrospect
analysi
also
show
baselin
level
serum
crp
level
elev
beyond
normal
rang
patient
avail
data
indic
presenc
inflamm
suggest
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
limit
report
includ
compassionateus
program
setup
short
period
time
determin
effect
siltuximab
reduc
serum
crp
level
understand
whether
crp
level
control
improv
outcom
patient
pneumoniaard
associ
addit
report
includ
short
followup
period
limit
number
patient
analysi
present
inform
medic
commun
potenti
role
siltuximab
treat
patient
infect
develop
pneumoniaard
requir
cpapniv
cohort
studi
match
patient
treat
siltuximab
treat
standard
therapi
hospit
ongo
report
full
clinic
outcom
upon
complet
extend
followup
anticip
natur
histori
diseas
shall
better
describ
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
zhou
et
al
aberr
pathogen
gmcsf
cell
inflammatori
monocyt
sever
pulmonari
syndrom
patient
new
coronaviru
biorxiv
submit
public
http
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
mechan
ventil
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
patient
receiv
second
dose
one
patient
move
intens
care
unit
subsequ
die
patient
two
infus
day
apart
patient
day
apart
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
worsen
condit
intub
death
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
figur
individu
patient
serum
crp
level
follow
siltuximab
treatment
day
follow
treatment
siltuximab
silutixmab
administr
day
line
repres
individu
patient
day
follow
siltuximab
administr
patient
serum
crp
level
mgdl
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
